Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus

Chandra Belani, J. D. Luketich, R. J. Landreaneau, R. Kim, R. K. Ramanathan, R. Day, P. F. Ferson, R. J. Keenan, M. Posner, J. Seeger, B. Lembersky

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Eighteen patients with esophageal carcinoma (16 adenocarcinoma, two squamous cell carcinoma) were treated with two cycles of induction chemotherapy consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 (3-hour infusion), cisplatin 20 mg/m2/d x 4 days, and 5-fluorouracil 1 g/m2/d (continuous infusion x 4 days) separated by a 28-day interval before surgical resection. After resection, patients received two more cycles of the same regimen. A thorough staging evaluation was performed before patients were enrolled in the study. The salient chemotherapy toxicities included grade 3 nausea (two patients), grade 3 vomiting (two patients), grades 3 and 4 diarrhea (one patient each), and grades 3 and 4 neutropenia (two and 10 patients, respectively). No deaths occurred due to toxicity. Surgical resection was attempted in all 18 patients (100%) after two cycles of induction chemotherapy. Esophageal resection was successfully completed in 17 patients. Liver metastases were noted at laparotomy in the one patient who subsequently did not undergo esophageal resection. Surgical complications were minor, and no postoperative deaths occurred. Fifteen patients received two additional cycles of the paclitaxel/5-fluorouracil/cisplatin regimen postoperatively, two received only one cycle, and one refused further therapy. Of 15 patients alive, 14 show no evidence of disease. The 1-year actuarial survival rate of this group of patients is 82%. In conclusion, the paclitaxel/5-fluorouracil/cisplatin combination is well tolerated and is an active regimen in esophageal carcinoma.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number6 SUPPL. 19
StatePublished - Dec 1 1997

Fingerprint

Paclitaxel
Fluorouracil
Cisplatin
Esophagus
Carcinoma
Induction Chemotherapy
Neutropenia
Laparotomy
Nausea
Vomiting
Squamous Cell Carcinoma
Diarrhea
Adenocarcinoma
Survival Rate
Neoplasm Metastasis

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Belani, C., Luketich, J. D., Landreaneau, R. J., Kim, R., Ramanathan, R. K., Day, R., ... Lembersky, B. (1997). Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. Seminars in Oncology, 24(6 SUPPL. 19).
Belani, Chandra ; Luketich, J. D. ; Landreaneau, R. J. ; Kim, R. ; Ramanathan, R. K. ; Day, R. ; Ferson, P. F. ; Keenan, R. J. ; Posner, M. ; Seeger, J. ; Lembersky, B. / Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. In: Seminars in Oncology. 1997 ; Vol. 24, No. 6 SUPPL. 19.
@article{d6b10aa60e4943f3b86a71813c9034f5,
title = "Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus",
abstract = "Eighteen patients with esophageal carcinoma (16 adenocarcinoma, two squamous cell carcinoma) were treated with two cycles of induction chemotherapy consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 (3-hour infusion), cisplatin 20 mg/m2/d x 4 days, and 5-fluorouracil 1 g/m2/d (continuous infusion x 4 days) separated by a 28-day interval before surgical resection. After resection, patients received two more cycles of the same regimen. A thorough staging evaluation was performed before patients were enrolled in the study. The salient chemotherapy toxicities included grade 3 nausea (two patients), grade 3 vomiting (two patients), grades 3 and 4 diarrhea (one patient each), and grades 3 and 4 neutropenia (two and 10 patients, respectively). No deaths occurred due to toxicity. Surgical resection was attempted in all 18 patients (100{\%}) after two cycles of induction chemotherapy. Esophageal resection was successfully completed in 17 patients. Liver metastases were noted at laparotomy in the one patient who subsequently did not undergo esophageal resection. Surgical complications were minor, and no postoperative deaths occurred. Fifteen patients received two additional cycles of the paclitaxel/5-fluorouracil/cisplatin regimen postoperatively, two received only one cycle, and one refused further therapy. Of 15 patients alive, 14 show no evidence of disease. The 1-year actuarial survival rate of this group of patients is 82{\%}. In conclusion, the paclitaxel/5-fluorouracil/cisplatin combination is well tolerated and is an active regimen in esophageal carcinoma.",
author = "Chandra Belani and Luketich, {J. D.} and Landreaneau, {R. J.} and R. Kim and Ramanathan, {R. K.} and R. Day and Ferson, {P. F.} and Keenan, {R. J.} and M. Posner and J. Seeger and B. Lembersky",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "6 SUPPL. 19",

}

Belani, C, Luketich, JD, Landreaneau, RJ, Kim, R, Ramanathan, RK, Day, R, Ferson, PF, Keenan, RJ, Posner, M, Seeger, J & Lembersky, B 1997, 'Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus', Seminars in Oncology, vol. 24, no. 6 SUPPL. 19.

Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. / Belani, Chandra; Luketich, J. D.; Landreaneau, R. J.; Kim, R.; Ramanathan, R. K.; Day, R.; Ferson, P. F.; Keenan, R. J.; Posner, M.; Seeger, J.; Lembersky, B.

In: Seminars in Oncology, Vol. 24, No. 6 SUPPL. 19, 01.12.1997.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus

AU - Belani, Chandra

AU - Luketich, J. D.

AU - Landreaneau, R. J.

AU - Kim, R.

AU - Ramanathan, R. K.

AU - Day, R.

AU - Ferson, P. F.

AU - Keenan, R. J.

AU - Posner, M.

AU - Seeger, J.

AU - Lembersky, B.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - Eighteen patients with esophageal carcinoma (16 adenocarcinoma, two squamous cell carcinoma) were treated with two cycles of induction chemotherapy consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 (3-hour infusion), cisplatin 20 mg/m2/d x 4 days, and 5-fluorouracil 1 g/m2/d (continuous infusion x 4 days) separated by a 28-day interval before surgical resection. After resection, patients received two more cycles of the same regimen. A thorough staging evaluation was performed before patients were enrolled in the study. The salient chemotherapy toxicities included grade 3 nausea (two patients), grade 3 vomiting (two patients), grades 3 and 4 diarrhea (one patient each), and grades 3 and 4 neutropenia (two and 10 patients, respectively). No deaths occurred due to toxicity. Surgical resection was attempted in all 18 patients (100%) after two cycles of induction chemotherapy. Esophageal resection was successfully completed in 17 patients. Liver metastases were noted at laparotomy in the one patient who subsequently did not undergo esophageal resection. Surgical complications were minor, and no postoperative deaths occurred. Fifteen patients received two additional cycles of the paclitaxel/5-fluorouracil/cisplatin regimen postoperatively, two received only one cycle, and one refused further therapy. Of 15 patients alive, 14 show no evidence of disease. The 1-year actuarial survival rate of this group of patients is 82%. In conclusion, the paclitaxel/5-fluorouracil/cisplatin combination is well tolerated and is an active regimen in esophageal carcinoma.

AB - Eighteen patients with esophageal carcinoma (16 adenocarcinoma, two squamous cell carcinoma) were treated with two cycles of induction chemotherapy consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 (3-hour infusion), cisplatin 20 mg/m2/d x 4 days, and 5-fluorouracil 1 g/m2/d (continuous infusion x 4 days) separated by a 28-day interval before surgical resection. After resection, patients received two more cycles of the same regimen. A thorough staging evaluation was performed before patients were enrolled in the study. The salient chemotherapy toxicities included grade 3 nausea (two patients), grade 3 vomiting (two patients), grades 3 and 4 diarrhea (one patient each), and grades 3 and 4 neutropenia (two and 10 patients, respectively). No deaths occurred due to toxicity. Surgical resection was attempted in all 18 patients (100%) after two cycles of induction chemotherapy. Esophageal resection was successfully completed in 17 patients. Liver metastases were noted at laparotomy in the one patient who subsequently did not undergo esophageal resection. Surgical complications were minor, and no postoperative deaths occurred. Fifteen patients received two additional cycles of the paclitaxel/5-fluorouracil/cisplatin regimen postoperatively, two received only one cycle, and one refused further therapy. Of 15 patients alive, 14 show no evidence of disease. The 1-year actuarial survival rate of this group of patients is 82%. In conclusion, the paclitaxel/5-fluorouracil/cisplatin combination is well tolerated and is an active regimen in esophageal carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0031473947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031473947&partnerID=8YFLogxK

M3 - Article

C2 - 9427275

AN - SCOPUS:0031473947

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 6 SUPPL. 19

ER -

Belani C, Luketich JD, Landreaneau RJ, Kim R, Ramanathan RK, Day R et al. Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. Seminars in Oncology. 1997 Dec 1;24(6 SUPPL. 19).